Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Subcutaneous infliximab maintained remission among patients with inflammatory bowel disease who ...
Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
Please provide your email address to receive an email when new articles are posted on . A fixed dose of 110 mg subcutaneous reslizumab was ineffective in reducing exacerbation frequency and daily ...
The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in ...
There were 259 subjects included in this study, including 122 children/adolescents and 137 adults (Table 1). The detailed demographic data are shown in Table 1. Skin thickness varied minimally with ...
The BLA is based on LEQEMBI subcutaneous (SC) sub-studies of the Phase 3 Clarity AD open-label extension (OLE) trial in individuals with early AD, which evaluated a range of subcutaneous doses. Data ...
This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback